View Author
patient cancer paclitaxel nephrectomy study survival tosedostat hypertension sunitinib treatment factor metastasised kidney cancer cycle cell carcinoma grade therapy metastatic grade 3 hypertension effect carcinoma analysis polymorphism kidney blood netherland baseline infusion trial cohort pressure cytoreductive nephrectomy sunitinib treatment disease value number table inhibitor propensity score haplotype change score diagnosis metastasised populationbased study prognostic factors performance cytoreductive aben kkh prognostic regression paclitaxel infusion metastase article reaction journal propensity result level vegfa bene ficial effect diastolic blood pressure metastatic kidney cancer surgery oncol association acg haplotype phase outcome treatment cycle center department blood pressure chr -79888 population-based study combination radboud university nijmegen systolic blood pressure tumour variable population-based
3 Most Recent Publications
|
Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension
(Article)
Eechoute, K. Veldt, A.A.M. van der Mathijssen, R.H.J. Boven, E. Oosting, R.S. Kappers, M.H.W. Wessels, J.A.M. Gelderblom, H. Guchelaar, H.J. Reyners, A.K.L. Herpen, C.M.L. Haanen, J.B. |
2012-10-01
|
|
Better survival in patients with metastasised kidney cancer after nephrectomy: A population-based study in the Netherlands
(Article)
Aben, K.K.H. Heskamp, S. Janssen-Heijnen, M.L.G. Koldewijn, E.L. Herpen, C.M.L. Kiemeney, L.A.L.M. Oosterwijk, E. Spronsen, D.J. van |
2011-04-04
|
|
A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours
(Article)
Herpen, C.M.L. Eskens, F.A.L.M. Jonge, M.J.A. de Desar, I. Hooftman, L. Bone, E. Timmerbonte, J.N.H. Verweij, J. |
2010-10-26
|
